Project Grant R37CA300232
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $663K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $708,990 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. The grant supports fundamental research investigating the microenvironmental and hepatocyte cell type-specific regulation of colorectal cancer (CRC) metastasis by the IL17 cytokine. The research aims to elucidate how IL17 signaling in hepatocytes and myeloid...
- Federal Grant Award Summary Cedars-Sinai Medical Center received an $858,798 Project Grant (R21) from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on August 18, 2025, with a completion date of July 31, 2027. The award supports a two-investigator research project investigating the role of extracellular vesicles (EVs) enclosed with circular RNA (circRNA) in modulating immune responses within the prostate cancer tumor microenvironment. The research...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $191,700 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. This award supports research investigating the etiology and tumor characteristics of early-onset pancreatic cancer. The project delivers two primary research services: (1) investigation of associations between early-onset pancreatic cancer...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $297,074 Project Grant to the University of California, Davis on August 8, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate Fluorescence Lifetime Imaging (FLIM) technology integrated into standard colonoscopy procedures for enhanced colorectal cancer detection. The project, which extends through July 31, 2030, will deliver three primary products: (1) a comprehensive in...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $382,449 Project Grant to the University of California, Los Angeles under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 16, 2025, with completion targeted for June 30, 2027. This research project develops and validates advanced dual-nuclei magnetic resonance imaging (MRI) techniques to non-invasively differentiate between recurrent brain metastases (RBM) and radiation-induced necrosis (RN)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...